Synlogic Beheer

Beheer criteriumcontroles 2/4

De CEO Synlogic is Tony Awad, benoemd in Mar2024, heeft een ambtstermijn van minder dan een jaar. De totale jaarlijkse vergoeding van { bedraagt $ 701.53K, bestaande uit 60.3% salaris en 39.7% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.29% van de aandelen van het bedrijf, ter waarde $ 48.42K. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 1 jaar en 8 jaar.

Belangrijke informatie

Tony Awad

Algemeen directeur

US$701.5k

Totale compensatie

Percentage CEO-salaris	60.3%
Dienstverband CEO	less than a year
Eigendom CEO	0.3%
Management gemiddelde ambtstermijn	less than a year
Gemiddelde ambtstermijn bestuur	8yrs

Recente managementupdates

Recent updates

Analyse CEO-vergoeding

Hoe is Tony Awad's beloning veranderd ten opzichte van Synlogic's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Sep 30 2024	n/a	n/a	-US$37m
Jun 30 2024	n/a	n/a	-US$49m
Mar 31 2024	n/a	n/a	-US$73m
Dec 31 2023	US$702k	US$423k	-US$57m
Sep 30 2023	n/a	n/a	-US$59m
Jun 30 2023	n/a	n/a	-US$65m
Mar 31 2023	n/a	n/a	-US$66m
Dec 31 2022	US$876k	US$411k	-US$66m
Sep 30 2022	n/a	n/a	-US$65m
Jun 30 2022	n/a	n/a	-US$63m
Mar 31 2022	n/a	n/a	-US$61m
Dec 31 2021	US$811k	US$391k	-US$61m
Sep 30 2021	n/a	n/a	-US$60m
Jun 30 2021	n/a	n/a	-US$57m
Mar 31 2021	n/a	n/a	-US$58m
Dec 31 2020	US$723k	US$359k	-US$59m
Sep 30 2020	n/a	n/a	-US$57m
Jun 30 2020	n/a	n/a	-US$57m
Mar 31 2020	n/a	n/a	-US$54m
Dec 31 2019	US$809k	US$325k	-US$51m

Compensatie versus markt: De totale vergoeding ($USD 701.53K ) Tony } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de UK markt ($USD 354.57K ).

Compensatie versus inkomsten: De vergoeding van Tony is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.

CEO

Tony Awad (44 yo)

less than a year

Tenure

US$701,534

Compensatie

Mr. Antoine Awad, also known as Tony, served as Chief Operating Officer at Synlogic, Inc. since July 2020 and was its Head of Technical Operations since December 12, 2018 until 2020 and serves as Principal...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Antoine Awad	Principal Executive Officer	less than a year	US$701.53k	0.29% $ 48.4k
Timothy Lu	Co-Founder & Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
James Collins	Co-Founder & Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Mary Dooley	VP, Head of Finance and Principal Financial Officer & Principal Accounting Officer	less than a year	geen gegevens	0.13% $ 21.7k
Ajay Munshi	Vice President of Corporate Development	no data	geen gegevens	geen gegevens
Neal Sondheimer	VP & Head of Clinical	1.4yrs	geen gegevens	geen gegevens
Jose-Carlos Gutierrez-Ramos	Advisor	no data	US$1.39m	geen gegevens

1.0yrs

Gemiddelde duur

44yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van 0A8U wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 1 jaar), wat duidt op een nieuw team.

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Timothy Lu	Co-Founder & Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
James Collins	Co-Founder & Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Richard Shea	Independent Director	7.3yrs	US$65.70k	0.0043% $ 714.2
Peter Barrett	Independent Chairman of the Board	10.3yrs	US$92.20k	0.18% $ 29.6k
Edward Mathers	Independent Director	12.1yrs	US$55.70k	0% $ 0
Michael Heffernan	Independent Director	3.9yrs	US$66.20k	0% $ 0
Nick Leschly	Independent Director	8.7yrs	US$55.70k	0.013% $ 2.2k
Paul Miller	Member Scientific Advisory Board	no data	US$956.81k	geen gegevens
Kristala Lanett Prather	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Cammie Lesser	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Christopher Voigt	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
James Flynn	Independent Director	less than a year	geen gegevens	geen gegevens

8.0yrs

Gemiddelde duur

60yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van 0A8U wordt beschouwd als ervaren (gemiddelde ambtstermijn 8 jaar).

Synlogic Beheer

Beheer criteriumcontroles 2/4

Belangrijke informatie

Recente managementupdates

Synlogic, Inc., Annual General Meeting, Dec 04, 2024

Synlogic, Inc. Announces Departure of Aoife Brennan as Chief Executive Officer

Synlogic, Inc. Appoints Chief Financial Officer Changes, Effective December 1, 2023

Synlogic, Inc. Appoints Dave Hava as Head of Research and Development

Synlogic, Inc. Announces Appointment of Brendan St. Amant as Corporate Secretary, Effective July 1, 2022

Synlogic Announces Appointment of Michael Jensen as Chief Financial Officer

Recent updates

Third quarter 2024 earnings released: US$0.01 loss per share (vs US$2.57 loss in 3Q 2023)

Synlogic, Inc., Annual General Meeting, Dec 04, 2024

New major risk - Share price stability

New major risk - Financial position

Second quarter 2024 earnings released: EPS: US$0.17 (vs US$3.21 loss in 2Q 2023)

New major risk - Financial position

First quarter 2024 earnings released: US$2.60 loss per share (vs US$3.39 loss in 1Q 2023)

Cable Car Capital Discloses its Views on Synlogic

Synlogic, Inc. Announces Departure of Aoife Brennan as Chief Executive Officer

Synlogic, Inc. Announces Publication of Preclinical and Clinical Data for SYNB1353 as a Potential Treatment for Classical Homocystinuria

Synlogic, Inc. Appoints Chief Financial Officer Changes, Effective December 1, 2023

Third quarter 2023 earnings released: US$2.57 loss per share (vs US$3.73 loss in 3Q 2022)

Synlogic, Inc. Announces Implementation of Reduction in Workforce

Synlogic, Inc. Announces Initiation of Synpheny-3 Global, Pivotal Phase 3 Study Evaluating SYNB1934 for Treatment of Phenylketonuria

Synlogic, Inc. Receives Rare Pediatric Disease Designation from FDA for SYNB1934 for Phenylketonuria

Synlogic, Inc. Appoints Dave Hava as Head of Research and Development

Synlogic Receives Non-Compliance Notice From Nasdaq

Synlogic Announces SYNB1353 Achieves Proof of Mechanism for Treatment of Homocystinuria and Provides Business Update

Synlogic Announces Positive Top-Line Phase 2 Data for Phenylketonuria (PKU) SYNB1934 Advances to Phase 3

Synlogic, Inc Announces Synthetic Biotic for Gout Developed in Partnership with Ginkgo Bioworks

Synlogic, Inc. to Report Q2, 2022 Results on Aug 11, 2022

Synlogic, Inc. Initiates Phase 1 Study of SYNB1353 for the Treatment of Homocystinuria

Synlogic, Inc. Announces Appointment of Brendan St. Amant as Corporate Secretary, Effective July 1, 2022

Synlogic, Inc. to Report Q1, 2022 Results on May 12, 2022

Synlogic to Present Data on Phenylketonuria and Homocystinuria Programs At the Society for Inherited Metabolic Disorders 43Rd Annual Meeting

Synlogic Announces Appointment of Michael Jensen as Chief Financial Officer

High number of new directors

Synlogic Presents Data on SYNB8802 for Enteric Hyperoxaluria at American Urological Association (AUA) Annual Meeting

High number of new directors

Synlogic Announces Initiation of Phase 1 Study of SYNB1934 for treatment of Phenylketonuria

Synlogic, Inc. Presents Additional Preclinical Data on Therapeutic Candidates SYNB1934 for Phenylketonuria (PKU) and SYNB8802 for Enteric Hyperoxaluria at Synthetic Biology: Engineering, Evolution & Design (SEED) Conference

Independent Director Chau Khuong has left the company

Synlogic, Inc. Provides Update on its Clinical and Preclinical Programs

Analyse CEO-vergoeding

CEO

Tenure

Compensatie

Leiderschapsteam

Gemiddelde duur

Gemiddelde leeftijd

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd